STOCK TITAN

Xenon Pharmaceuticals Inc - XENE STOCK NEWS

Welcome to our dedicated news page for Xenon Pharmaceuticals (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenon Pharmaceuticals's position in the market.

Rhea-AI Summary
Xenon Pharmaceuticals Inc. reports strong financial position with $930 million to support Phase 3 programs in epilepsy and major depressive disorder. Completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025. Conference call scheduled for today at 4:30 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
earnings
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) will release its Q4 and full year 2023 financial results on February 29, 2024, after the U.S. financial markets close. A conference call/webcast will follow at 4:30 pm Eastern Time. Investors can access the live webcast on Xenon's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
earnings
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) outlines progress within its pipeline programs and key milestones for 2024. The company anticipates completing patient enrollment in the XEN1101 Phase 3 X-TOLE2 clinical trial for focal onset seizures in the second half of 2024 and plans to initiate the XEN1101 Phase 3 program for major depressive disorder in 2024. The company also highlighted the positive data generated in the Phase 2 proof-of-concept X-NOVA clinical trial for depression and the ongoing progress in the Phase 3 epilepsy clinical trials. Additionally, Xenon is actively planning for late-stage development of XEN1101 in depression and evaluating potential development in additional neurological indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.23%
Tags
none
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Ian Mortimer, President and CEO, to present on January 8, 2024. Live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) closed its underwritten public offering of 9,846,157 common shares, generating approximately $345.0 million in gross proceeds. The offering included 1,384,615 shares from the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The public offering price was $32.50 per common share, and the pre-funded warrants were offered at a price of $32.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets acted as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
offering
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) to provide updates on neurology programs at AES 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and pre-funded warrants, with expected gross proceeds of approximately $300.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
offering
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced the commencement of an underwritten public offering of $225.0 million of its common shares and pre-funded warrants to purchase common shares. The proposed offering is subject to market conditions and will be made by means of a written prospectus and prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
offering
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) reported topline results from the X-NOVA clinical trial evaluating XEN1101 for major depressive disorder, showing clinically meaningful drug activity and early onset of efficacy, with a favorable tolerability and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.78%
Tags
clinical trial
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announces that the Phase 2 clinical trial for NBI-921352 in adult patients with focal onset seizures (FOS) failed to show a meaningful reduction in seizure frequency. No further development with NBI-921352 in FOS is planned at this time. Xenon will review the data to understand potential implications for the second ongoing study with NBI-921352 in SCN8A-developmental epileptic encephalopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
none
Xenon Pharmaceuticals Inc

Nasdaq:XENE

XENE Rankings

XENE Stock Data

3.53B
64.55M
0.51%
102.49%
3.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Burnaby

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.